Loading
BioNTech SE Stock: price and insider trades · United States
US·Mcap US$22.4B
BioNTech SE: what insiders have been doing
BioNTech SE, founded in 2008, is a listed company based in Mainz, Germany. Its directors and officers file their transactions with SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for BioNTech SE logged 28 filings by 3 insiders.
Only sales appear on the open market, 27 sales in all totalling €78.3M, filed by 2 insiders. Biggest ticket of the year: €6.2M, sold by Sahin Ugur and made public on 6 October 2026 (0.029% of market cap).
The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 28 filings here. Since 2026, the database holds no purchases and 27 sales by insiders of the company.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
28
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€78M
27 ops. · all time
Who traded when
BuySaleUgur Sahin26 sales
Sierk Poetting1 sale
Analyst consensus: bullish or bearish?
Analysts rate BioNTech SE Buy (bullish), based on 20 analysts. Average price target: US$116.29.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,001 of 24,148 companies
31.9
score / 100
Value26
Quality38
FCF yld-1.3%
Earn yld-5.2%
EV/EBITDA·
ROE-9.3%
Gross mgn78%
Net mgn-40%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$89.01
Analyst consensus
20 analystsBuy
US$76.09Target US$116.29(+31%)US$144.18
Income statement
RevenueUS$2.9B
Gross profitUS$2.2B78% margin
EBITDA-US$653.8M-23% margin
Net income-US$1.1B-63.6% margin
Valuation
PER (forward)-18.0x
P/Book1.1x
Beta1.25
Balance sheet & cash
Market capUS$22.4B
Total debtUS$267.4M
Free Cash Flow-US$293M
Debt / Equity2%
Profitability & ownership
ROE-9.3%
ROA-5.4%
% insiders57.2%
% institutions20.4%
Last declaration on 9 October 2026
Declarations28 total
27,000 shares@ US$92.31420.011% mcap3.0% of flowOrdinary SharesSEC:0002123975-26-000035:0
36,209 shares@ US$95.37330.015% mcap4.2% of flowOrdinary SharesSEC:0002123975-26-000035:1
24,000 shares@ US$95.85970.0094% mcap3.0% of flowOrdinary SharesSEC:0002123975-26-000033:0
72,000 shares@ US$97.23120.029% mcap9.4% of flowOrdinary SharesSEC:0002123975-26-000031:0
21,000 shares@ US$96.80930.0083% mcap2.7% of flowOrdinary SharesSEC:0002123975-26-000031:1
17,000 shares@ US$97.45560.0067% mcap2.5% of flowOrdinary SharesSEC:0002123975-26-000029:0
17,000 shares@ US$96.72490.0067% mcap2.5% of flowOrdinary SharesSEC:0002123975-26-000029:1
34,000 shares@ US$98.25910.014% mcap5.3% of flowOrdinary SharesSEC:0002123975-26-000027:0
32,000 shares@ US$98.12030.013% mcap5.0% of flowOrdinary SharesSEC:0002123975-26-000027:1
27,000 shares@ US$98.68820.012% mcap4.7% of flowOrdinary SharesSEC:0002123975-26-000025:0
34,000 shares@ US$98.46820.015% mcap5.9% of flowOrdinary SharesSEC:0002123975-26-000025:1
30,000 shares@ US$99.40270.013% mcap5.9% of flowOrdinary SharesSEC:0002123975-26-000023:0
39,000 shares@ US$98.99130.017% mcap7.7% of flowOrdinary SharesSEC:0002123975-26-000023:1
33,000 shares@ US$97.80970.014% mcap6.3% of flowOrdinary SharesSEC:0002123975-26-000021:0
46,000 shares@ US$100.71820.021% mcap9.1% of flowOrdinary SharesSEC:0002123975-26-000021:1
34,000 shares@ US$98.59830.015% mcap6.6% of flowOrdinary SharesSEC:0002123975-26-000019:0
30,000 shares@ US$96.22430.013% mcap5.7% of flowOrdinary SharesSEC:0002123975-26-000019:1
34,000 shares@ US$96.48930.014% mcap6.4% of flowOrdinary SharesSEC:0002123975-26-000017:0
15,000 shares@ US$96.08930.0063% mcap2.8% of flowOrdinary SharesSEC:0002123975-26-000017:1
45,000 shares@ US$96.93380.019% mcap8.5% of flowOrdinary SharesSEC:0002123975-26-000015:0
41,000 shares@ US$99.44670.018% mcap7.9% of flowOrdinary SharesSEC:0002123975-26-000015:1
20,500 shares@ US$96.30670.0086% mcap3.8% of flowOrdinary SharesSEC:0002123975-26-000013:0
37,000 shares@ US$99.20320.016% mcap7.1% of flowOrdinary SharesSEC:0002123975-26-000011:0
36,000 shares@ US$97.78180.015% mcap6.8% of flowOrdinary SharesSEC:0002123975-26-000011:1
45,000 shares@ US$102.84960.020% mcap9.0% of flowOrdinary SharesSEC:0002123975-26-000008:0
25 of 28 declarations
About BioNTech SE
BioNTech SE is a German biopharmaceutical company focused on developing immunotherapies and vaccines. It is best known for its COVID-19 vaccine developed in collaboration with Pfizer.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
